Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update
Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million ...
Hosted on MSN4d
FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen
The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell ...
The American Journal of Managed Care3d
Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell ...
Medscape3d
FDA Approves Grafapex (Treosulfan) for HSCT Conditioning
After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.
Targeted Oncology2d
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...
Cure Today2d
FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...
MedPage Today5d
FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell ...
Stockhouse4d
Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update
GRAFAPEX™ (treosulfan) for injection is approved by the FDA for sale and use in the United States only and is not intended for export outside the United States. Medexus makes no representation that ...